BTAI BioXcel Therapeutics Inc

Price (delayed)

$30.7

Market cap

$858.65M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.11

Enterprise value

$586.85M

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel's drug re-innovation approach leverages existing approved drugs and/or clinically ...

Highlights
The equity is up by 43% since the previous quarter
BTAI's quick ratio is up by 39% since the previous quarter
BTAI's debt is up by 38% year-on-year but it is down by 5% since the previous quarter
BioXcel Therapeutics's net income has shrunk by 86% YoY and by 7% QoQ
BTAI's EPS is down by 43% year-on-year

Key stats

What are the main financial stats of BTAI
Market
Shares outstanding
27.97M
Market cap
$858.65M
Enterprise value
$586.85M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.83
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$99.8M
EBITDA
-$99.57M
Free cash flow
-$82.08M
Per share
EPS
-$4.11
Free cash flow per share
-$3.29
Book value per share
$10.86
Revenue per share
$0
TBVPS
$11.26
Balance sheet
Total assets
$281.11M
Total liabilities
$13.7M
Debt
$1.26M
Equity
$267.41M
Working capital
$264.22M
Liquidity
Debt to equity
0
Current ratio
22.24
Quick ratio
21.95
Net debt/EBITDA
2.73
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-42.5%
Return on equity
-45.3%
Return on invested capital
N/A
Return on capital employed
-37.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BTAI stock price

How has the BioXcel Therapeutics stock price performed over time
Intraday
0.29%
1 week
4.28%
1 month
28.45%
1 year
-36.43%
YTD
-33.55%
QTD
5.64%

Financial performance

How have BioXcel Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$99.86M
Net income
-$99.83M
Gross margin
N/A
Net margin
N/A
BioXcel Therapeutics's net income has shrunk by 86% YoY and by 7% QoQ
The company's operating income has shrunk by 85% YoY and by 7% QoQ

Growth

What is BioXcel Therapeutics's growth rate over time

Valuation

What is BioXcel Therapeutics stock price valuation
P/E
N/A
P/B
2.83
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
BTAI's EPS is down by 43% year-on-year
The equity is up by 43% since the previous quarter
BTAI's price to book (P/B) is 38% lower than its last 4 quarters average of 4.6

Efficiency

How efficient is BioXcel Therapeutics business performance
The company's return on equity has surged by 60% YoY and by 19% QoQ
BioXcel Therapeutics's return on assets has surged by 53% YoY and by 17% QoQ

Dividends

What is BTAI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BTAI.

Financial health

How did BioXcel Therapeutics financials performed over time
The total assets has grown by 40% from the previous quarter
BTAI's quick ratio is up by 39% since the previous quarter
BTAI's debt is 100% smaller than its equity
BioXcel Therapeutics's debt to equity has plunged by 100% from the previous quarter and by 100% YoY
The equity is up by 43% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.